Predict your next investment

Cygnal Therapeutics company logo
HEALTHCARE | Biotechnology
cygnaltx.com

See what CB Insights has to offer

Executives

8

Board of Directors

1

Cygnal Therapeutics Board of Director

1 Board of directors

Cygnal Therapeutics has 1 board of directors, including Avak Kahvejian.

Name

Firm

Work History

Other Seats

Avak Kahvejian

Avak Kahvejian, Ph.D. is a life sciences inventor, entrepreneur, and CEO. Since 2011, he has been a partner at Flagship Pioneering, where he leads a team to invent and launch new therapeutic platforms. His work has led to the creation of multiple high-value public and private companies including Cygnal Therapeutics (pioneering new drugs that target neuronal pathways for the treatment of cancer, and autoimmune/inflammation disorders); Codiak BioSciences (developing engineered exosome therapeutics as cancer treatments); Rubius Therapeutics (NASDAQ: RUBY); developing Red Cell Therapeutics, engineered red blood cells capable of providing potent and prolonged therapy for rare diseases, cancer, and autoimmunity; and Seres Therapeutics (NASDAQ: MCRB); the first microbiome therapy platform. At Cygnal, Avak served as founding president and CEO from 2017 until the end of 2018, and currently serves as Chief Innovation Officer, leading the establishment and application of a neuronal biology platform for target and drug discovery in the fields of oncology and immunology. At Rubius, Avak served as founding President and CEO from 2013 to 2017, and then as CIO until the end of 2018. There he established the Rubius Erythrocyte Design (RED)™ platform and conceived and developed dozens of Red Cell Therapeutics (RCTs)™ spanning a range of therapeutic modalities including enzyme therapies, immuno-oncology and oncology therapies, and tolerogenic drugs. Avak also serves as a board member at Laronde, Codiak, and as CEO of multiple FlagshipLabs companies including Cellarity, Ring, FL50, and FL56. Prior to Flagship, Avak was VP of Business Development at Helicos BioSciences, which developed and commercialized the world’s first single molecule DNA sequencer. Avak serves on the board of the International Institute of New England, an institution which creates opportunities for refugees and immigrants to succeed through resettlement, education, career advancement and pathways to citizenship. He is also on the board of the Canadian Entrepreneurs of New England, an organization dedicated to assisting Canadian entrepreneurs build ties with the Boston life sciences and technology ecosystems. Avak earned his Ph.D. and B.Sc. in Biochemistry from McGill University in Montreal, Canada.

Cellarity, Codiak Biosciences, Codiak Biosciences, and Ring Therapeutics

Name

Avak Kahvejian

Firm

Work History

Avak Kahvejian, Ph.D. is a life sciences inventor, entrepreneur, and CEO. Since 2011, he has been a partner at Flagship Pioneering, where he leads a team to invent and launch new therapeutic platforms. His work has led to the creation of multiple high-value public and private companies including Cygnal Therapeutics (pioneering new drugs that target neuronal pathways for the treatment of cancer, and autoimmune/inflammation disorders); Codiak BioSciences (developing engineered exosome therapeutics as cancer treatments); Rubius Therapeutics (NASDAQ: RUBY); developing Red Cell Therapeutics, engineered red blood cells capable of providing potent and prolonged therapy for rare diseases, cancer, and autoimmunity; and Seres Therapeutics (NASDAQ: MCRB); the first microbiome therapy platform. At Cygnal, Avak served as founding president and CEO from 2017 until the end of 2018, and currently serves as Chief Innovation Officer, leading the establishment and application of a neuronal biology platform for target and drug discovery in the fields of oncology and immunology. At Rubius, Avak served as founding President and CEO from 2013 to 2017, and then as CIO until the end of 2018. There he established the Rubius Erythrocyte Design (RED)™ platform and conceived and developed dozens of Red Cell Therapeutics (RCTs)™ spanning a range of therapeutic modalities including enzyme therapies, immuno-oncology and oncology therapies, and tolerogenic drugs. Avak also serves as a board member at Laronde, Codiak, and as CEO of multiple FlagshipLabs companies including Cellarity, Ring, FL50, and FL56. Prior to Flagship, Avak was VP of Business Development at Helicos BioSciences, which developed and commercialized the world’s first single molecule DNA sequencer. Avak serves on the board of the International Institute of New England, an institution which creates opportunities for refugees and immigrants to succeed through resettlement, education, career advancement and pathways to citizenship. He is also on the board of the Canadian Entrepreneurs of New England, an organization dedicated to assisting Canadian entrepreneurs build ties with the Boston life sciences and technology ecosystems. Avak earned his Ph.D. and B.Sc. in Biochemistry from McGill University in Montreal, Canada.

Other Seats

Cellarity, Codiak Biosciences, Codiak Biosciences, and Ring Therapeutics

Cygnal Therapeutics Management Team

8 Team Members

Cygnal Therapeutics has 8 executives. Cygnal Therapeutics's current Chief Executive Officer, President is Pearl Huang.

Name

Work History

Title

Status

Pearl Huang

Roche Venture Fund, GlaxoSmithKline, BeiGene, Merck & Co., and GSK USA

Chief Executive Officer, President

Current

John Wagner

Chief Medical Officer

Current

Daniel Blom

Senior Vice President

Current

Pauline McGowan

Senior Vice President

Current

Ljiljana Minwalla

CiVi Biopharma, Mesoblast, Protein Sciences, Mount Sinai School of Medicine, and New York University

Senior Vice President

Current

Name

Pearl Huang

John Wagner

Daniel Blom

Pauline McGowan

Ljiljana Minwalla

Work History

Roche Venture Fund, GlaxoSmithKline, BeiGene, Merck & Co., and GSK USA

CiVi Biopharma, Mesoblast, Protein Sciences, Mount Sinai School of Medicine, and New York University

Title

Chief Executive Officer, President

Chief Medical Officer

Senior Vice President

Senior Vice President

Senior Vice President

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.